Targeted Delivery with CM-SMRTs
Our proprietary CM-SMRTs platform selectively enables therapeutic protein expression in cardiomyocytes while minimizing off-target expression
Preclinical studies demonstrate selective expression in cardiomyocytes (red) using CM-SMRTs compared to conventional modRNA delivery
Our Mission
Cardiovascular disease remains the leading cause of death worldwide. Current treatments only manage symptoms or restore blood flow, but there are no approved therapies capable of rebuilding damaged myocardium
Our Objective
SeleRNA is developing modRNA therapeutics designed to restore cardiac function by activating repair and regeneration after injury
Our Approach
Using our CM-SMRTs platform, we aim to selectively and transiently express therapeutic proteins in cardiomyocytes while minimizing off-target effects
Why It Matters
We seek to move treatment beyond supportive care toward true myocardial recovery with regenerative therapeutics designed to improve functional performance
